KBB-N2

KBB-N2 is a tetracyclic triterpene compound currently under preclinical investigation for the treatment of multiple myeloma. It acts as a targeted agent that disrupts mitochondrial function by inhibiting the mitochondrial electron transport chain (ETC) complexes I and III. This inhibition leads to the excessive generation of intracellular reactive oxygen species (ROS) and the suppression of the antioxidant enzyme catalase, ultimately triggering tumor cell death through ROS-mediated apoptosis and activation of the P53 pathway. In vivo studies have demonstrated that KBB-N2 significantly inhibits tumor growth and extends survival in multiple myeloma mouse models, showing lower toxicity to normal hematopoietic stem cells compared to standard treatments like lenalidomide.